Size | Price | Stock | Qty |
---|---|---|---|
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
Mycophenolate Mofetil (Cellcept, Mycophenolic acid, Myfortic, RS-61443), an antimetabolite immunosuppressant, is a potent, non-competitive, selective and reversible inhibitor of inosine monophosphate dehydrogenase I/II with IC50 of 39 nM and 27 nM, respectively. Mycophenolic acid is an immunosuppressant drug used to prevent rejection in organ transplantation. Mycophenolate mofetil is an ester prodrug of the active immunosuppressant mycophenolic acid (MPA). MPA also produces the concentration-dependent inhibition of proliferation of ConA-stimulated T cells, LPS-stimulated B cells and alloantigen-specific T cells.
ln Vitro |
Inosine monophosphate dehydrogenase is a crucial enzyme that T and B lymphocytes use for the de novo production of guanosine nucleotides [1].
|
||
---|---|---|---|
ln Vivo |
|
||
Animal Protocol |
|
||
References |
[1]. Simmons WD, et al. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection. Drug Saf. 1997;17(2):75-92.
[2]. Fulton B, et al. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs. 1996;51(2):278-298. |
Molecular Formula |
C23H31NO7
|
---|---|
Molecular Weight |
433.4947
|
Exact Mass |
433.21
|
Elemental Analysis |
C, 63.73; H, 7.21; N, 3.23; O, 25.83
|
CAS # |
128794-94-5
|
Related CAS # |
Mycophenolate Mofetil-d4;1132748-21-0;Mycophenolate mofetil hydrochloride;116680-01-4
|
Appearance |
Solid powder
|
SMILES |
O1C([H])([H])C([H])([H])N(C([H])([H])C([H])([H])OC(C([H])([H])C([H])([H])/C(/C([H])([H])[H])=C(\[H])/C([H])([H])C2C(=C3C(=O)OC([H])([H])C3=C(C([H])([H])[H])C=2OC([H])([H])[H])O[H])=O)C([H])([H])C1([H])[H]
|
Synonyms |
RS61443;Mycophenolic acid, Mycophenolate mofetil, Cellcept, Myfortic, RS-61443;Mycophenolate mofetil (free acid);
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.77 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.77 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.77 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 0.5% methylcellulose:20 mg/mL Solubility in Formulation 5: 33.33 mg/mL (76.89 mM) in Cremophor EL (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.3069 mL | 11.5343 mL | 23.0686 mL | |
5 mM | 0.4614 mL | 2.3069 mL | 4.6137 mL | |
10 mM | 0.2307 mL | 1.1534 mL | 2.3069 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05627739 | Recruiting | Drug: Mycophenolate Mofetil | Vogt-Koyanagi-Harada Disease Mycophenolate Mofetil |
October 1, 2021 | August 23, 2017 | |
NCT03200002 | Completed | Drug: Cyclophosphamide Drug: Mycophenolate Mofetil |
To Compare the Effects of Mycophenolate Mofetil With Cyclophosphamide in Neplaese Lupus Nephritis Patients |
Chitwan Medical College | January 1, 2014 | Phase 2 |
NCT03678987 | Completed | Diagnostic Test: P-MPA concentration Drug: mycophenolic acid |
Systemic Sclerosis Gastrointestinal Complication |
Region Skane | September 13, 2018 | |
NCT02743247 | Completed | Drug: Tacrolimus Drug: Mycophenolate mofetil |
Healthy Volunteers | Seoul National University Hospital | October 2015 | Phase 1 |